vs
Embecta Corp.（EMBC）与Mativ Holdings, Inc.（MATV）财务数据对比。点击上方公司名可切换其他公司
Mativ Holdings, Inc.的季度营收约是Embecta Corp.的1.8倍（$463.1M vs $261.2M），Mativ Holdings, Inc.净利率更高（21.8% vs 16.9%，领先4.9%），Mativ Holdings, Inc.同比增速更快（1.0% vs -0.3%），Embecta Corp.自由现金流更多（$16.6M vs $8.0M），过去两年Mativ Holdings, Inc.的营收复合增速更高（-3.8% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
EMBC vs MATV — 直观对比
营收规模更大
MATV
是对方的1.8倍
$261.2M
营收增速更快
MATV
高出1.2%
-0.3%
净利率更高
MATV
高出4.9%
16.9%
自由现金流更多
EMBC
多$8.6M
$8.0M
两年增速更快
MATV
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $463.1M |
| 净利润 | $44.1M | $100.8M |
| 毛利率 | 61.9% | 18.8% |
| 营业利润率 | 31.9% | 2.2% |
| 净利率 | 16.9% | 21.8% |
| 营收同比 | -0.3% | 1.0% |
| 净利润同比 | — | 6620.0% |
| 每股收益（稀释后） | $0.74 | $1.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCMATV
| Q4 25 | $261.2M | $463.1M | ||
| Q3 25 | $264.0M | $513.7M | ||
| Q2 25 | $295.5M | $525.4M | ||
| Q1 25 | $259.0M | $484.8M | ||
| Q4 24 | $261.9M | $458.6M | ||
| Q3 24 | $286.1M | $498.5M | ||
| Q2 24 | $272.5M | $523.8M | ||
| Q1 24 | $287.2M | $500.2M |
净利润EMBCMATV
| Q4 25 | $44.1M | $100.8M | ||
| Q3 25 | $26.4M | $-3.2M | ||
| Q2 25 | $45.5M | $-9.5M | ||
| Q1 25 | $23.5M | $-425.5M | ||
| Q4 24 | $0 | $1.5M | ||
| Q3 24 | $14.6M | $-20.8M | ||
| Q2 24 | $14.7M | $-1.4M | ||
| Q1 24 | $28.9M | $-28.0M |
毛利率EMBCMATV
| Q4 25 | 61.9% | 18.8% | ||
| Q3 25 | 60.0% | 19.3% | ||
| Q2 25 | 66.7% | 19.7% | ||
| Q1 25 | 63.4% | 15.0% | ||
| Q4 24 | 60.0% | 16.9% | ||
| Q3 24 | 60.7% | 18.8% | ||
| Q2 24 | 69.8% | 20.8% | ||
| Q1 24 | 64.6% | 16.8% |
营业利润率EMBCMATV
| Q4 25 | 31.9% | 2.2% | ||
| Q3 25 | 21.4% | 3.1% | ||
| Q2 25 | 31.8% | 3.8% | ||
| Q1 25 | 24.3% | -88.8% | ||
| Q4 24 | 11.0% | 0.6% | ||
| Q3 24 | 9.2% | 1.4% | ||
| Q2 24 | 20.5% | 2.0% | ||
| Q1 24 | 13.6% | -2.8% |
净利率EMBCMATV
| Q4 25 | 16.9% | 21.8% | ||
| Q3 25 | 10.0% | -0.6% | ||
| Q2 25 | 15.4% | -1.8% | ||
| Q1 25 | 9.1% | -87.8% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | 5.1% | -4.2% | ||
| Q2 24 | 5.4% | -0.3% | ||
| Q1 24 | 10.1% | -5.6% |
每股收益（稀释后）EMBCMATV
| Q4 25 | $0.74 | $1.87 | ||
| Q3 25 | $0.44 | $-0.06 | ||
| Q2 25 | $0.78 | $-0.18 | ||
| Q1 25 | $0.40 | $-7.82 | ||
| Q4 24 | $0.00 | $0.03 | ||
| Q3 24 | $0.24 | $-0.38 | ||
| Q2 24 | $0.25 | $-0.03 | ||
| Q1 24 | $0.50 | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $84.2M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $-613.1M | $498.7M |
| 总资产 | $1.1B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 2.07× |
8季度趋势，按日历期对齐
现金及短期投资EMBCMATV
| Q4 25 | $201.3M | $84.2M | ||
| Q3 25 | $225.5M | $97.1M | ||
| Q2 25 | $230.6M | $95.6M | ||
| Q1 25 | $209.3M | $84.0M | ||
| Q4 24 | $210.0M | $94.3M | ||
| Q3 24 | $267.5M | $162.2M | ||
| Q2 24 | $275.1M | $133.4M | ||
| Q1 24 | $299.8M | $128.9M |
总债务EMBCMATV
| Q4 25 | — | $1.0B | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
股东权益EMBCMATV
| Q4 25 | $-613.1M | $498.7M | ||
| Q3 25 | $-650.6M | $397.4M | ||
| Q2 25 | $-669.6M | $416.6M | ||
| Q1 25 | $-736.2M | $428.2M | ||
| Q4 24 | $-768.8M | $858.5M | ||
| Q3 24 | $-738.3M | $882.3M | ||
| Q2 24 | $-763.7M | $898.0M | ||
| Q1 24 | $-769.6M | $906.9M |
总资产EMBCMATV
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $2.0B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.1B | $2.1B | ||
| Q4 24 | $1.1B | $2.4B | ||
| Q3 24 | $1.3B | $2.6B | ||
| Q2 24 | $1.3B | $2.6B | ||
| Q1 24 | $1.2B | $2.7B |
负债/权益比EMBCMATV
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 2.63× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 2.67× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 1.30× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $8.0M |
| 自由现金流率自由现金流/营收 | 6.4% | 1.7% |
| 资本支出强度资本支出/营收 | 0.2% | 2.4% |
| 现金转化率经营现金流/净利润 | 0.39× | 0.19× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $93.8M |
8季度趋势，按日历期对齐
经营现金流EMBCMATV
| Q4 25 | $17.2M | $19.3M | ||
| Q3 25 | $84.0M | $72.8M | ||
| Q2 25 | $81.2M | $57.6M | ||
| Q1 25 | $31.8M | $-15.9M | ||
| Q4 24 | $-5.3M | $24.1M | ||
| Q3 24 | $26.6M | $37.6M | ||
| Q2 24 | $-2.1M | $46.1M | ||
| Q1 24 | $24.3M | $-13.0M |
自由现金流EMBCMATV
| Q4 25 | $16.6M | $8.0M | ||
| Q3 25 | $76.7M | $66.7M | ||
| Q2 25 | $80.8M | $48.9M | ||
| Q1 25 | $31.7M | $-29.8M | ||
| Q4 24 | $-6.8M | $2.0M | ||
| Q3 24 | — | $25.5M | ||
| Q2 24 | $-11.8M | $37.4M | ||
| Q1 24 | $20.9M | $-25.1M |
自由现金流率EMBCMATV
| Q4 25 | 6.4% | 1.7% | ||
| Q3 25 | 29.1% | 13.0% | ||
| Q2 25 | 27.3% | 9.3% | ||
| Q1 25 | 12.2% | -6.1% | ||
| Q4 24 | -2.6% | 0.4% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | -4.3% | 7.1% | ||
| Q1 24 | 7.3% | -5.0% |
资本支出强度EMBCMATV
| Q4 25 | 0.2% | 2.4% | ||
| Q3 25 | 2.8% | 1.2% | ||
| Q2 25 | 0.1% | 1.7% | ||
| Q1 25 | 0.0% | 2.9% | ||
| Q4 24 | 0.6% | 4.8% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 3.6% | 1.7% | ||
| Q1 24 | 1.2% | 2.4% |
现金转化率EMBCMATV
| Q4 25 | 0.39× | 0.19× | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | — | 16.07× | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
